The relationship between the rs6265 polymorphism of the BDNF gene and the level of serum neurotrophic factor in patients with Parkinson’s disease

Objectives. To evaluate clinical features and serum brain-derived neurotrophic factor (BDNF) levels in groups of patients with Parkinson’s disease (PD) with different genotypes of the rs6265 polymorphic variant of the BDNF gene. Materials and methods. Serum BDNF levels were assessed in 134 patients with PD as part of a multiplex panel of biomarkers for neurodegenerative diseases (HNDG3MAG-36K). Alleles for analysis of the rs6265 polymorphic variant of the BDNF gene were discriminated in groups of patients and controls (n = 192), matched in terms of sex, age, and ethnic composition, by real-time PCR using TaqMan probes. Results. Comparison of the distributions of rs6265 genotypes and alleles between the patient and control groups revealed no signifi cant differences. Serum BDNF levels varied signifi cantly by genotype (rs6265) in PD patients. For individuals with the AA genotype, a minimum mean serum BDNF level was noted (320.1 ± ± 164.6 pg/ml), which was signifi cantly different from the corresponding value for individuals with the GA (2944.2 ± 1590.6 pg/ml; p = 0.0001) and GG (2949.4 ± 1620.6 pg/ml; p = 3.9·10–5) genotypes. The BDNF concentration was found to differ signifi cantly between patients with different forms of PD (p = 0.0007) and increased as the Hoehn and Yahr stage of disease progressed (p = 1.0·10–6). Conclusions. These studies found no association between the rs6265 polymorphic variant of the BDNF gene and the development of PD in the study population. Variability in the mean serum BDNF level depending on the genotype of the BDNF gene polymorphism studied here was established in patients with PD with a number of clinical features.

Читать в источнике